FDA & Peptides in 2026: The PCAC Compounding Vote, Retatrutide's Phase 3 Data & What's Legal in Canada

By the ThePeptide.ca Research Team · Living document, reviewed against primary sources · Last updated July 31, 2026

The last week of July 2026 produced two of the most consequential peptide-science headlines of the decade — on the same two days. On July 23–24, the U.S. FDA's Pharmacy Compounding Advisory Committee (PCAC) voted on whether seven widely studied peptides should become eligible for legal pharmacy compounding, and on July 23, Eli Lilly released pivotal Phase 3 data for the triple-agonist retatrutide. Both are routinely — and incorrectly — described online as "FDA approvals." Neither one is. Days later, Health Canada announced a permanent court injunction against a Canadian peptide retailer — the enforcement development that actually matters north of the border. This guide explains exactly what happened, what the studies showed, what the words actually mean, and what the law is for Canadian researchers.

Quick answer

In July 2026 the FDA's advisory committee voted 8–6 to back BPC-157 and KPV for the 503A compounding list — over the objection of the FDA's own scientists — while Eli Lilly reported the final pivotal Phase 3 retatrutide readouts. Neither event is an FDA drug approval, and neither changes anything in Canada. What did change in Canada is enforcement: the Superior Court of Québec granted Health Canada a permanent injunction against retailer Canlab Research, barring it from selling and advertising unauthorized injectable peptides to Canadians. Health Canada's position is unchanged — injectable peptides are prescription drugs, and "research use only" labelling is not a legal exemption.

8–6
PCAC vote backing BPC-157
3
Pivotal retatrutide readouts
Permanent
Court injunction: sales and advertising
0
US rulings that change Canadian law
Live update · July 31, 2026 — Health Canada enforcement

Health Canada has obtained a permanent injunction against a Canadian peptide retailer. The Superior Court of Québec granted the order against Canlab Research on June 11, 2026; Health Canada announced it publicly in late July. The injunction permanently prohibits the company — and its representatives — from manufacturing, testing, distributing or selling unauthorized injectable peptides, from assisting others in doing so, and from advertising these products "including through any website or social media platform accessible with a Canadian Internet Protocol (IP) address." Health Canada said the company had been selling unauthorized peptide drugs "and promoting them with many unproven health claims, despite repeated enforcement actions." See what the injunction means below.

Earlier update · July 24, 2026 — PCAC outcome

The two-day PCAC meeting concluded July 24. The committee's headline action was an 8–6 vote (one abstention) to recommend BPC-157 and KPV for the 503A Bulk Drug Substances List — notably against FDA review staff, who had recommended against inclusion citing insufficient efficacy evidence. Votes on the remaining compounds (TB-500, MOTS-C, and the July 24 agenda of emideltide/DSIP, Semax and Epitalon) were being finalised as the meeting closed; we will update this page as the official record is posted. A PCAC recommendation is advisory only — it is not FDA approval and not a final rule.

Research Use Only ThePeptide.ca sells peptides strictly for laboratory and research use only. Nothing in this article is medical, legal, or regulatory advice, a dosing recommendation, or an encouragement to use any substance for human consumption. All clinical figures cited are outcomes reported in published trials or company releases, presented for scientific reference only. Regulatory status is summarised for information and can change — verify against primary sources.

Key takeaways

  • "Approval" is the wrong word. The FDA did not approve any peptide as a drug in July 2026. The PCAC vote is about compounding eligibility under Section 503A — a different, narrower question — and it is only an advisory recommendation.
  • The committee sided with access over its own scientists. PCAC voted 8–6 to back BPC-157 and KPV even though FDA review staff recommended against, citing a lack of efficacy evidence.
  • Canada now has a permanent court injunction in this sector. The Superior Court of Québec barred Canlab Research from selling or advertising unauthorized injectable peptides to Canadian IP addresses — a clear signal that Canadian enforcement in this sector has moved from advisories to court orders.
  • Retatrutide's Phase 3 package is now complete but unapproved. TRIUMPH-1, -2 and -3 have all read out and met their primary endpoints; Lilly plans regulatory submissions in 2027. It is not approved anywhere as of this writing.
  • The cardiovascular readout was neutral, not protective. TRIUMPH-3's MACE result did not reach significance — an honest limitation worth stating plainly.
  • None of the U.S. action changes Canadian law. FDA compounding decisions have no legal effect in Canada, where Health Canada maintains that injectable peptides are prescription drugs and RUO labelling grants no exemption.

What Actually Happened in July 2026

Two separate regulatory and scientific events landed within 24 hours of each other, and the internet promptly blended them into a single false headline: "the FDA approved peptides." Keeping them distinct is the whole point.

Event 1 — the FDA PCAC compounding hearing (July 23–24). The FDA's Pharmacy Compounding Advisory Committee met at the agency's White Oak campus to consider whether seven peptides — BPC-157, KPV, TB-500, MOTS-C, emideltide (DSIP), Semax and Epitalon — should be added to the 503A Bulk Drug Substances List, the list that governs which substances licensed compounding pharmacies may legally prepare. The committee voted 8–6 (one abstention) to recommend BPC-157 and KPV, a result made unusual by the fact that the FDA's own review scientists had recommended against inclusion.

Event 2 — retatrutide's pivotal Phase 3 readouts (July 23). Eli Lilly reported topline results from retatrutide's TRIUMPH-2 and TRIUMPH-3 trials, completing the core Phase 3 dataset for the first triple GIP/GLP-1/glucagon agonist. These are clinical-trial results supporting a future regulatory filing — not an approval, and not a compounding decision.

Event 3 — Canada's enforcement escalation (announced late July). Separately, Health Canada announced that it had secured a permanent injunction from the Superior Court of Québec against retailer Canlab Research. Unlike the U.S. events, this one carries direct legal force in Canada — and it is the development Canadian researchers and suppliers should actually be reading closely.

The one-line distinction: the PCAC vote is about whether pharmacies may compound certain peptides in the U.S.; the retatrutide data is about whether a pharmaceutical company can eventually get a new drug approved. Both are U.S. processes with no legal effect in Canada. The Canadian injunction is the one with teeth here.
↑ Back to top

FDA Approval vs 503A Compounding vs "Research Use Only": Three Different Things

Most confusion in this space comes from collapsing three distinct legal categories into one word. Here is how they actually differ.

Pathway What it is What it is not
FDA drug approval A manufacturer proves safety and efficacy in clinical trials; the FDA approves a specific product for a specific indication (e.g. semaglutide as Wegovy). Not what the PCAC does. Retatrutide has not reached this stage.
503A compounding eligibility Whether a licensed pharmacy may compound a bulk substance for an individual patient. Governed by the 503A Bulks List; PCAC advises on additions. Not a finding that the substance is safe, effective, or "approved" as a drug.
Research use only (RUO) A material sold for in-vitro / laboratory research, not for human or veterinary use. A product category, not an approval. Not a regulatory clearance — and, per Health Canada, not a legal exemption in Canada.

When a headline says a peptide was "approved," the accurate translation is almost always one of the narrower events above. For a fuller treatment of the Canadian side of these definitions, see our guide to whether research peptides are legal in Canada. ↑ Back to top

The FDA PCAC Hearing (July 23–24, 2026)

To understand why an advisory-committee vote made national news, you need the backstory of Section 503A. Under the Federal Food, Drug, and Cosmetic Act, compounding pharmacies may only use bulk drug substances that are either the subject of a USP monograph, a component of an approved drug, or on the FDA's 503A Bulks List. Substances the FDA flags as posing "significant safety risks" are placed in a restricted Category 2, which effectively bars pharmacies from compounding them.

What was on the agenda

Seven peptides were scheduled for review across the two days:

Day Peptides reviewed
July 23 BPC-157 (acetate and free-base forms), KPV, TB-500 (LKKTETQ fragment), MOTS-C
July 24 Emideltide (DSIP), Semax, Epitalon

The vote — and why it was notable

The committee voted 8–6, with one abstention, to recommend adding BPC-157 and KPV to the 503A Bulks List. What made the result striking was the split with the FDA's own staff: agency reviewers had recommended against inclusion, and specifically noted a "lack of evidence to support the effectiveness of BPC-157 (free base) and BPC-157 acetate" for the proposed indication (ulcerative colitis). Committee members who voted to include argued that prescribing decisions should rest with physicians and pharmacists; those against pointed to thin human-efficacy data. National outlets framed the outcome as an advisory panel backing peptides "despite opposition from agency scientists."

Votes on the remaining compounds — TB-500 and MOTS-C on July 23, and the July 24 agenda of emideltide (DSIP), Semax and Epitalon — were still being tallied and posted as the meeting closed. We will update this section against the official FDA record.

Crucial caveat: a PCAC recommendation is advisory and non-binding. The FDA is not required to follow it, and any change to the Bulks List proceeds through formal rulemaking that typically takes six to twelve months. Even a favourable vote does not make BPC-157 an FDA-approved drug — it remains unapproved, and the vote concerns U.S. compounding only.
↑ Back to top

How We Got Here: A Short Timeline

Date Development
Sept 2023 FDA moves 19 widely studied peptides (BPC-157, TB-500, CJC-1295, Ipamorelin, MOTS-C, Epitalon, DSIP and others) to restricted Category 2, citing immunogenicity and impurity concerns.
Dec 2023 Health Canada issues a consumer warning about unauthorized injectable peptides sold by Canlab Research — the first step in a multi-year enforcement chain.
Feb 2026 HHS Secretary R.F. Kennedy Jr. publicly signals that most restricted peptides should move back to Category 1, arguing the restrictions "created the gray market."
Apr 2026 FDA formally removes 12 peptides from Category 2 (Federal Register, effective late April) after nominators withdrew — reopening a U.S. compounding pathway.
Apr 9, 2026 Health Canada issues a forceful advisory warning against injecting peptides bought online, naming BPC-157, retatrutide and others among seized products.
Jun 11, 2026 The Superior Court of Québec grants Health Canada a permanent injunction against Canlab Research, barring the sale and advertising of unauthorized injectable peptides to Canadian IP addresses.
Jul 23–24, 2026 PCAC reviews seven peptides for the 503A Bulks List; votes 8–6 to back BPC-157 and KPV. Same week, retatrutide reports pivotal Phase 3 data.
Late Jul 2026 Health Canada publicly announces the Canlab injunction, bringing the order to the sector's attention.

For the deeper Canadian regulatory framework behind this timeline, see our companion guide on research peptide regulations in Canada. ↑ Back to top

Retatrutide's Phase 3 Data: What the Studies Actually Showed

Retatrutide (Eli Lilly code LY-3437943) is the first triple GIP/GLP-1/glucagon receptor agonist to reach Phase 3. Its registrational program, TRIUMPH, now has three pivotal readouts. The summary below describes what each trial studied; the reported endpoints themselves are in the company releases and publications cited at the foot of this page, and are not reproduced here.

Trial Population Primary endpoint met Timepoint
TRIUMPH-1 Obesity, no diabetes (n≈2,339) Yes (with a pre-specified extension) 80 / 104 weeks
TRIUMPH-2 Type 2 diabetes + obesity (n≈1,152) Yes 80 weeks
TRIUMPH-3 Severe obesity + established CVD (n≈1,949) Yes (cardiovascular endpoint neutral) 80 weeks

The pattern reported is consistent with the incretin literature, with the largest effects in the non-diabetic population (TRIUMPH-1) and somewhat smaller effects in people with type 2 diabetes (TRIUMPH-2) — a difference seen across this drug class.

Reading these numbers correctly: two estimands, two answers

Retatrutide's headline figures differ between sources because Lilly reported TRIUMPH-1 under two separate estimands, and most coverage quotes one without saying which. An efficacy estimand estimates the effect if participants had remained on treatment; a treatment-regimen estimand measures everyone randomised regardless of discontinuation. Both are legitimate, and the efficacy estimand always yields the larger number. Lilly published both for TRIUMPH-1; see the company release cited below for the figures.

The most widely circulated headline figure is an efficacy-estimand result at 104 weeks in the 532 participants with BMI ≥35 who continued into the pre-specified extension — not the whole trial population at 80 weeks. When a retatrutide weight-loss figure is quoted without an estimand label and a timepoint, treat it as unsourced.

Tolerability, reported plainly

Efficacy figures travel further than safety figures, so the tolerability data is worth stating directly. In TRIUMPH-1, discontinuation due to adverse events rose across the trial arms, reaching 11.3% in the highest-strength arm versus 4.9% on placebo. Nausea was the most common adverse event, alongside diarrhoea, constipation and vomiting. In other words, the arm producing the largest effect is also the arm roughly one in nine participants stopped because of side effects.

The type 2 diabetes data is now peer-reviewed

Beyond the TRIUMPH obesity program, the companion diabetes trial TRANSCEND-T2D-1 has been published in The Lancet (online June 6, 2026). In 537 adults across 48 sites, retatrutide reduced HbA1c by −1.94% from a baseline mean of 7.9%, versus −0.81% on placebo (difference −1.12%, P<0.0001), with 82–89% of participants reaching HbA1c below 7.0%. Gastrointestinal adverse events were mild to moderate and no severe hypoglycaemia was reported. This is the first retatrutide Phase 3 dataset to clear peer review rather than arrive by press release — a meaningful distinction when weighing evidence quality.

The cardiovascular result: neutral, reported honestly

TRIUMPH-3 was the first retatrutide trial to examine major adverse cardiovascular events (MACE) in a higher-risk population. The result was neutral rather than protective: 44 MACE in the retatrutide arms versus 52 on placebo, with a five-point MACE hazard ratio of 0.82 (95% CI 0.55–1.22) — a confidence interval crossing 1.0, so not statistically significant. Lilly noted events "occurred less frequently than anticipated in both arms," limiting what an 80-week trial can detect. Cardiovascular risk factors, by contrast, improved clearly in the highest-strength arm: roughly −37% triglycerides, −16.5% non-HDL cholesterol and −51.2% high-sensitivity CRP. Whether those translate into fewer events is the job of the larger, longer TRIUMPH-Outcomes study.

Lilly's Kenneth Custer said the results give the company "the clinical data package to support global submissions," with a regulatory filing anticipated in 2027. In other words: pivotal data in hand, but not yet submitted and not yet approved. The full mechanism, pharmacology, purity and sourcing picture is covered in our retatrutide research guide, and the class context in our semaglutide vs tirzepatide vs retatrutide comparison. ↑ Back to top

Health Canada's Permanent Injunction: Enforcement With Teeth

On June 11, 2026, the Superior Court of Québec granted Health Canada a permanent injunction against Canlab Research, an online retailer of injectable peptides. Health Canada announced the order publicly in late July 2026. It is a marked escalation in Canadian enforcement for this sector, and it is worth reading carefully — because of what it prohibits.

What the injunction prohibits

The order permanently bars Canlab Research and its representatives from:

  • Manufacturing, testing, distributing or selling unauthorized injectable peptides;
  • Assisting any other party in doing so; and
  • Advertising these products — or assisting others in advertising them — "including through any website or social media platform accessible with a Canadian Internet Protocol (IP) address."
The detail most coverage missed: this injunction reaches advertising, not just sales — and it defines reach by Canadian IP accessibility rather than by where a company is incorporated or hosted. That is a materially broader test than most operators assume applies to them.

Why Health Canada acted

Health Canada stated that the company had been "selling unauthorized peptide drugs on various websites and promoting them with many unproven health claims, despite repeated enforcement actions." The escalation is visible in the record: a consumer warning in December 2023, a Ministerial Order directing the company to stop advertising and selling unauthorized health products, a public advisory in April 2026, and finally the injunction. The Department emphasised that "unauthorized peptide drugs can be dangerous and may contain ingredients that have not been assessed for safety, effectiveness or quality."

What it signals for the sector

Read plainly, the conduct that drew this action was the combination of unauthorized drug sales plus unproven health claims, sustained after repeated warnings. That is a specific pattern, not a blanket judgment on every supplier. But it establishes that Health Canada will pursue court orders in this sector, and that promotional language — not just the transaction — is squarely within scope. For any operator, the practical implication is that marketing discipline is now a compliance control, not a stylistic choice: therapeutic claims, human-use framing, and dosing guidance are precisely the conduct that escalated this case.

↑ Back to top

What None of the U.S. Action Changes in Canada

A recurring misconception is that FDA decisions ripple directly into Canadian law. They do not. The two countries run separate regulatory systems, and the July 2026 U.S. developments have no legal effect north of the border.

Health Canada's position was restated forcefully in its April 9, 2026 advisory, "Think twice before injecting peptides bought online," and has since been backed by court order. Its core points:

  • Most synthetic injectable peptides are prescription drugs under the Food and Drugs Act. Without a Drug Identification Number (DIN), they are unauthorized drugs.
  • Selling unauthorized health products is illegal — such products have not been assessed for safety, efficacy or quality.
  • "Research use only" labelling is not an exemption. Health Canada stated explicitly that this labelling "does not make these products legal or exempt from regulatory requirements."
  • Enforcement is active and now judicial. Beyond Health Canada and CBSA intercepting unauthorized shipments at the border, the Department has now obtained a permanent Superior Court injunction covering both sale and advertising.

So while U.S. compounding pharmacies may gain access to BPC-157, that is a U.S. compounding pathway that does not exist in Canada. Authorized peptide drugs in Canada — such as semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro) — carry a DIN and require a prescription. Research-grade peptides are a distinct category sold strictly for laboratory use. The compliance takeaway is unchanged but sharper: work only with suppliers who hold disciplined research-use-only positioning, avoid therapeutic and dosing claims, and provide batch-linked third-party documentation. Our guide to peptide legality in Canada covers this in full. ↑ Back to top

The Peptides Under Review: An Evidence Snapshot

Brief, research-context summaries of the compounds at the centre of the July 2026 hearing. None is an approved drug in Canada; all are discussed here as research materials.

Peptide Research context
BPC-157 15-amino-acid synthetic sequence derived from gastric juice; among the most-studied peptides in preclinical tissue-repair models. Reviewed by PCAC for ulcerative colitis; FDA staff flagged limited efficacy evidence.
TB-500 Synthetic fragment (LKKTETQ) related to thymosin beta-4; studied preclinically for cell migration and repair. Frequently paired with BPC-157 in the literature.
KPV Tripeptide fragment of α-MSH studied for anti-inflammatory signalling in preclinical models. Recommended alongside BPC-157 in the PCAC vote.
MOTS-C Mitochondrial-derived peptide studied in metabolic-regulation research.
Emideltide (DSIP) Delta sleep-inducing peptide; studied for neuromodulatory pathways. On the July 24 agenda.
Semax ACTH-derived peptide studied in neuroprotection/cognition research (notably in Russia). On the July 24 agenda.
Epitalon Tetrapeptide studied for telomerase and circadian pathways in aging research. On the July 24 agenda.

The metabolic GLP-1 peptides — semaglutide, tirzepatide and retatrutide — sit in a separate conversation: the first two are approved drugs in some markets, while retatrutide remains investigational. ↑ Back to top

What Canadian Researchers Should Do Now

The regulatory noise doesn't change day-to-day best practice; if anything the Canlab injunction sharpens it.

  • Read the word carefully. "Compounding vote" and "Phase 3 data" are not "FDA approval." Treat any source that conflates them as unreliable.
  • Verify third-party documentation. Insist on batch-specific Certificates of Analysis from an independent lab — see how to read a peptide COA.
  • Check purity and identity data. HPLC purity (typically ≥98%) and mass-spectrometry identity confirmation, traceable to a specific lot.
  • Prioritise domestic Canadian sourcing. In-country shipping avoids CBSA holds and the thermal-cycling risk that degrades lyophilized peptides at the border.
  • Treat promotional language as a compliance signal. The Canlab injunction turned on unproven health claims. A supplier making therapeutic or dosing claims is telling you something about its regulatory posture — and its longevity.

Read: buying research peptides in Canada →

↑ Back to top

Frequently Asked Questions

Did the FDA approve peptides in July 2026?

No. The FDA did not approve any peptide as a drug in July 2026. Its advisory committee (PCAC) voted to recommend adding BPC-157 and KPV to the 503A compounding list — a narrower, advisory action about what pharmacies may prepare. That is not a drug approval, and the recommendation is non-binding.

What did Health Canada's permanent injunction actually do?

On June 11, 2026 the Superior Court of Québec granted Health Canada a permanent injunction against the online retailer Canlab Research. It permanently bars the company from manufacturing, testing, distributing or selling unauthorized injectable peptides, and from advertising them through any website or social media platform accessible with a Canadian IP address. Health Canada announced the order publicly in late July 2026.

Does the injunction make research peptides illegal in Canada?

No. The injunction applies to one named company. It does not change the underlying law, which was already clear: injectable peptides without a Drug Identification Number are unauthorized drugs, and "research use only" labelling is not a legal exemption. What the injunction changes is the demonstrated willingness of Health Canada to seek court orders — and the fact that advertising, not just selling, is within scope.

What did the PCAC vote actually decide?

On July 23–24, 2026 the Pharmacy Compounding Advisory Committee voted 8–6 (one abstention) to recommend BPC-157 and KPV for the 503A Bulk Drug Substances List, over the objection of FDA review staff. Votes on TB-500, MOTS-C, DSIP, Semax and Epitalon were being finalised as the meeting closed. Any actual change follows formal FDA rulemaking over roughly 6–12 months.

Is BPC-157 now FDA-approved?

No. A favourable PCAC recommendation concerns compounding eligibility, not drug approval. BPC-157 remains an unapproved substance; the vote is advisory and applies only to U.S. compounding.

Does the FDA decision make peptides legal in Canada?

No. FDA and PCAC actions have no legal effect in Canada. Health Canada regulates most injectable peptides as prescription drugs, and its April 2026 advisory stated that "research use only" labelling does not create a legal exemption.

Was retatrutide approved by the FDA?

No. In July 2026 Eli Lilly reported pivotal Phase 3 data (TRIUMPH-2 and TRIUMPH-3), completing its core Phase 3 dataset. Lilly said it plans regulatory submissions in 2027. Retatrutide is investigational and not approved by the FDA or Health Canada.

Where can I read retatrutide's Phase 3 results?

The TRIUMPH-1, TRIUMPH-2 and TRIUMPH-3 figures come from Eli Lilly company releases, and the companion diabetes trial TRANSCEND-T2D-1 is the only Phase 3 dataset published in a peer-reviewed journal to date. Consult those primary sources directly, and note that reported figures vary depending on which estimand is quoted.

Has any retatrutide Phase 3 data been peer-reviewed?

Yes. The companion type 2 diabetes trial TRANSCEND-T2D-1 was published in The Lancet online on June 6, 2026, reporting an HbA1c reduction of −1.94% over 40 weeks in 537 adults. Most of the TRIUMPH obesity figures circulating online still come from company press releases rather than peer-reviewed publication.

Did retatrutide reduce heart attacks and strokes?

Not demonstrably. TRIUMPH-3's cardiovascular (MACE) result was neutral and not statistically significant (hazard ratio 0.82, 95% CI 0.55–1.22), because events were rarer than expected in both arms. It did improve cardiovascular risk factors. The larger TRIUMPH-Outcomes trial is designed to answer the events question.

What is the difference between compounding and drug approval?

Drug approval means the FDA has reviewed a manufacturer's clinical data and authorised a specific product for a specific use. 503A compounding eligibility only governs whether pharmacies may prepare a bulk substance for individual patients — it is not a safety-and-efficacy approval of a marketed drug.

Sources & Further Reading

  1. Health Canada. "Health Canada obtains permanent injunction preventing Canlab Research's illegal sale of injectable peptides in Canada." July 2026. canada.ca.
  2. U.S. FDA. "July 23–24, 2026: Meeting of the Pharmacy Compounding Advisory Committee." fda.gov.
  3. Regulatory Affairs Professionals Society (RAPS). "FDA advisory committee backs two controversial peptides." July 2026. raps.org.
  4. The Hill. "FDA panel votes to add peptides to permitted compounding list despite opposition from agency scientists." July 2026. thehill.com.
  5. Orrick. "FDA Peptide Compounding Vote: What to Watch at the July PCAC Meeting." July 2026. orrick.com.
  6. U.S. FDA. "Certain Bulk Drug Substances for Use in Compounding That May Present Significant Safety Risks." fda.gov.
  7. Eli Lilly and Company. "Lilly's triple agonist, retatrutide, successful in two additional Phase 3 obesity trials" (TRIUMPH-2 and TRIUMPH-3). July 23, 2026. investor.lilly.com.
  8. "Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial." The Lancet, published online June 6, 2026. doi:10.1016/S0140-6736(26)00967-0.
  9. Giblin K, Kaplan LM, Somers VK, Le Roux CW, Hunter DJ, Wu Q, Lalonde A, Ahmad N, Bethel MA. "Retatrutide for the treatment of obesity, obstructive sleep apnea and knee osteoarthritis: Rationale and design of the TRIUMPH registrational clinical trials." Diabetes Obes Metab. 2026. PMID 41090431.
  10. Heerspink HJL, van Raalte DH, Bjornstad P, et al. "Rationale, design and baseline characteristics of the TRANSCEND-CKD trial of retatrutide in patients with chronic kidney disease." Nephrol Dial Transplant. 2026. PMID 41160422.
  11. Katsi V, Koutsopoulos G, Fragoulis C, Dimitriadis K, Tsioufis K. "Retatrutide — A Game Changer in Obesity Pharmacotherapy." Biomolecules. 2025. PMID 40563436.
  12. Fierce Biotech. "Lilly's triple-G drug hits 22.6% weight loss, but impact on reducing cardio risk is less clear." July 2026. fiercebiotech.com.
  13. HCPLive. "Retatrutide Meets Phase 3 Weight-Loss Endpoints in 2 Obesity Trials." July 2026. hcplive.com.
  14. Health Canada. Public Advisory: "Think twice before injecting peptides bought online." April 9, 2026. recalls-rappels.canada.ca.
  15. Jastreboff AM, et al. "Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial." N Engl J Med. 2023;389(6):514-526. nejm.org.

Changelog. July 31, 2026 (rev. 2) — Verified TRIUMPH-1 figures against Lilly's primary trial release and added the full efficacy vs treatment-regimen estimand table; added tolerability and discontinuation data; added primary-literature citations (PMID 41090431, 41160422, 40563436) and the full Lancet title for TRANSCEND-T2D-1; removed comparative characterisations of the injunction that could not be verified against a primary source. July 31, 2026 — Added Health Canada's permanent injunction against Canlab Research (Superior Court of Québec, June 11, 2026), including the advertising prohibition; added a dedicated enforcement section and timeline entries; added the peer-reviewed TRANSCEND-T2D-1 Lancet publication (June 6, 2026); added an explainer on efficacy vs treatment-regimen estimands in reported trial figures. July 24, 2026 — Added PCAC vote outcome.

Final Disclaimer — Research Use Only This article is for informational and educational purposes only and does not constitute legal, medical, or regulatory advice. Regulatory status is summarised as of July 31, 2026 and can change; verify against primary sources before relying on it. All products sold by ThePeptide.ca are intended strictly for laboratory and scientific research purposes, are not approved by Health Canada or the FDA, and are not for human or veterinary consumption. This page is maintained as a living document and will be updated as the record is finalised.
Back to blog